Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Albumin · 1 trial · 1 indication
Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) includes 12 questions classified into 3 subdomains: bulbar function (3 questions), fine and gross motor skills (6 questions), and respiratory function (3 questions) to assess the level self sufficiency. Each task was graded according to a 5-point scale from 0 (incapable) to 4 (normal ability) with a total score from 0 (worst) to 48 (best).
| Arm | Type | Description |
|---|---|---|
| Albumin | EXPERIMENTAL | Plasma exchange with Albumin |
| Name | Type | Description |
|---|---|---|
| Albumin | BIOLOGICAL | 27 plasma exchange procedures using Albumin 5% (estimated 3000 mL per plasma exchange) as replacement solution: * three weeks of intensive treatment with two plasma exchanges per week * twenty-one weeks of maintenance treatment with one weekly plasma exchange |
Inclusion Criteria: * Signed written-informed consent. * Subjects over 18 years of age, and less than 70 years old. * Subjects with a definite, possible, or probable diagnosis of ALS, according to the revised El Escorial criteria. * Subjects having experienced their first ALS symptoms within 18 mon...
Albumin is an investigational therapy being studied for Alzheimer's Disease. In a Phase 2 clinical trial, it was evaluated in combination with immunoglobulin for the treatment of Alzheimer's Disease. The study enrolled 347 participants and has been completed.
Albumin is being studied for Amyotrophic Lateral Sclerosis (ALS). A Phase 2 clinical trial evaluated the efficacy and safety of plasma exchange with albumin in patients with ALS. The study enrolled 13 participants in Spain and has been completed.
Albumin is being developed by Grifols, S.A., a biopharmaceutical company. The company's stock is traded under the ticker symbol GRFS. Grifols is conducting clinical research to evaluate albumin as a potential treatment for neurological conditions.
Albumin is in Phase 2 clinical development. It has been studied in completed Phase 2 trials for both Alzheimer's Disease and Amyotrophic Lateral Sclerosis. The drug is investigational and has not been approved for these indications.
Albumin has been studied in two completed Phase 2 clinical trials. NCT01561053 evaluated albumin and immunoglobulin in Alzheimer's Disease with 347 participants in the United States and Spain. NCT02479802 evaluated plasma exchange with albumin in Amyotrophic Lateral Sclerosis with 13 participants in Spain.
Albumin is the investigational drug being developed by Grifols, S.A. for neurological conditions. The clinical trials NCT01561053 and NCT02479802 are evaluating albumin as a therapeutic intervention for Alzheimer's Disease and Amyotrophic Lateral Sclerosis, respectively.